A retrospective study to predict pituitary immune-related adverse events (irAEs) and to provide safe treatment with Immune checkpoint inhibitors and elucidating the pathogenesis of various irAEs
Latest Information Update: 06 Apr 2020
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Gastric cancer; Malignant melanoma; Non-small cell lung cancer
- Focus Adverse reactions; Pharmacodynamics
Most Recent Events
- 06 Apr 2020 New trial record
- 28 Mar 2020 Results published in the European Journal of Cancer